Eli Lilly
LLY · NYSE
Bulios Fair Price
$886.9
20.5% downside
Current Price
$1,115
According to Bulios Fair Price, LLY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Eli Lilly and Company (LLY) is an American pharmaceutical company with a long history and significant influence in the global pharmaceutical market. The company specializes in research, development, and manufacturing of medicinal products in various therapeutic areas, including diabetology, oncology, neurology, and others. Eli Lilly offers a wide range of pharmaceutical products and treatment approaches that help improve the health and quality of life of patients worldwide. The company invests in innovation and research to bring new drugs and treatment methods that could potentially change the way diseases are treated. Eli Lilly and Company is a respected name in the pharmaceutical industry and has a strong foundation for further growth and development. Investing in Eli Lilly and Company (LLY) shares may represent an attractive choice for investors seeking a reliable and innovative company in the healthcare sector.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
David A. Ricks
Employees
50,000
Headquarters
Indianapolis
Upcoming events
Earnings
Upcoming earnings report